Seeking Alpha
18 Nov 2026, 09:41 UTC · 1h ago
Philip Morris: Still A Buy To Me After The ZYN Price Cut
Impact · against what's priced in
Philip Morris faces a short-term headwind as a ZYN value adjustment likely slows revenue growth, making the 11.6% CAGR required by the current price harder to achieve. While earnings guidance remains stable, the revenue pressure on the oral nicotine category challenges the current growth assumptions.
- PM−0.30
Challenges what's priced in
- The price assumes
Can IQOS and Zyn sustain a growth pace fast enough to meet the 11.6% overall revenue CAGR the price requires
Increasing ZYN pouch counts from 15 to 20 at unchanged prices creates revenue pressure for roughly three quarters, undermining the acceleration needed to hit the 11.6% overall revenue CAGR the market expects.
What PM's price assumes · Sep 1

Search tags




